Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
December 03, 2024 06:50 ET
|
Eton Pharmaceuticals
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
November 25, 2024 06:50 ET
|
Eton Pharmaceuticals
Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s existing pediatric endocrinology focusAmglidia has been...
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 12, 2024 16:01 ET
|
Eton Pharmaceuticals
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024...
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
November 07, 2024 07:00 ET
|
Eton Pharmaceuticals
- Product has patent protection through 2043 -- Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 - DEER PARK, Ill., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 06, 2024 16:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
October 03, 2024 06:30 ET
|
Eton Pharmaceuticals
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to Bolster Eton’s Commercial Pediatric...
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
August 22, 2024 16:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 08, 2024 16:01 ET
|
Eton Pharmaceuticals
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew drug application (NDA) for ET-400 accepted...
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 30, 2024 17:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
July 15, 2024 16:05 ET
|
Eton Pharmaceuticals
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton...